Company: NCEL
Filing Date: 2025-02-10
Form Type: F-3
Source: 0001213900-25-011823
Chunk: 16

Company: NewcelX Ltd.
Filing Date: 2025-02-10
Form: F-3
Chunk 16
---
 of Science. Professor Revel received the Israel Prize for the invention and development of Rebif ®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is currently listed on the Tel Aviv Stock Exchange (TASE: KDST).

<div align='center'>7</div>

Company Overview

Kadimastem is a clinical stage
biotechnology company, with a unique platform for cell therapy that enables the production of off-the-shelf cell-based products for the
treatment of unmet medical needs. Kadimastem operates in the field of development of cell therapy, regenerative medicine, for the treatment
of, among others, ALS, an incurable disease, for which Kadimastem received an orphan drug designation status from the FDA, as well as
cell therapy in the field of regenerative medicine for the treatment of diabetes, a disease that affects hundreds of millions of people
worldwide, and its product has the potential to provide a cure for the disease. Kadimastem intends to be a leading company in the field
of regenerative medicine products for the treatment of neurodegenerative diseases and a cure for diabetes.

Kadimastem is developing revolutionary
regenerative therapies based on stem cells-derived therapeutic cells, moving away from the traditional curative therapies. The technology
has been developed as a platform enabling the manufacturing of islet-like endocrine cells and glia restricted progenitors thus having
potential applications for diabetes, and for neurodegenerative diseases such as ALS. The therapy is scalable and industrialized, to be
commercialized as a stable “off the shelf” product and reduce the cost of treatments. For this, Kadimastem uses pluripotent
cells (e.g. embryonic stem cells - hESCs) that have a unique ability to multiply infinitely without losing their “naivety”
and to be able to become any cell type. The cell therapy products manufactured under Good Manufacturing Practices, or GMP, guidelines
(similar to traditional therapeutics) in order to reach optimal clinical results. Kadimastem developed a new process to differentiate
the cells in the lab to their mature phenotype, before their implantation to the patient, unlike other technologies which transplant immature
precursor cells. Thus, Kadimastem believes that its process will markedly enhance the efficiency of the treatment. The transplantation
of immature cells depends on exact signals from the surrounding tissues to support their maturation into functional cells. This process
in vivo cannot be controlled, and as such